Forteo approved for glucocorticoid-induced osteoporosis
The FDA has approved Forteo (teriparatide [rDNA origin] injection, from Lilly) for the treatment of osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women at high risk of fracture.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.